27/05/2008Geneva Health Forum25 Recommendations Governments should be aware of the low availability and large differences Reasons for the large differences should be investigated Differential pricing initiatives should be promoted Procurement in the public sector should be funded Competition should be stimulated Quality assured generics should be promoted Price and availability reporting mechanism should be available at each WHO-region More detailed information per country is needed
{}